Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Slides:

Advertisements

Similar presentations

Immunity 6.5 Antibodies.

Advertisements

Monoclonal antibodies Hybridoma Technique. Monoclonal antibodies (mAb or moAb) Monoclonal antibodies are:  monospecific antibodies that are identical.

MONOCLONAL ANTIBODIES

White blood cells & the immune system What does it mean to be immune to something? Leucocyte (WBC) Phagocytes (engulf & destroy) = Inflammation Lymphocytes.

Adaptive Immunity: Specific Defenses of the host

Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.

Immunology Chapter 16, Lecture 1 Richard L. Myers, Ph.D. Department of Biology Southwest Missouri State Temple Hall 227 Telephone:

Highlights of Immune System. Topic Outline Overview of the Immune System 1 st and 2 nd lines of Defense The Immune System  B cells  The antibody & antibody.

Microbiology B.E Pruitt & Jane J. Stein AN INTRODUCTION EIGHTH EDITION TORTORA FUNKE CASE Chapter 17, part B Specific Defenses of the Host: The Immune.

Immunogenetics chapter 21 pp. pp Lines of Defense Physical and Chemical Physical and Chemical Immune system Immune system 3 rd line 1 st and.

Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma by Maurizio Chiriva-Internati, Zhiqing Wang, Emanuela Salati, Klaus.

Vice President, Cancer Therapeutics, Inc.

HOST DEFENCE AGAINST TUMORS:

Ramucirumab Protein chemical formula : C6374H9864N1692O1996S46

M1 – Immunology EFFECTOR T CELL FUNCTIONS (Part I) March 27, 2009 Ronald B. Smeltz, Ph.D. Microbiology and Immunology

Chapter 43 The Immune System.

Atezolizumab Drugbank ID : DB11595.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Structure and function of blinatumomab. A

chimeric antigen receptor T-cell therapy for ALL

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

Chemotherapy and Cancer Stem Cells

Avoiding Immune Detection

Bispecific antibodies Creative Biolabs is a specialized manufacturer of bispecific antibodies based on our advanced technology and years of experience.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Bispecific Creative Biolabs is a specialized manufacturer of bispecific antibodies based on our advanced technology and years of experience. We are available.

Bispecific t cell engager Creative Biolabs possesses unchallenged experience in bispecific T- cell engager (BiTE) synthesis. We elaborately integrate multiple.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Biosimilar monoclonal antibodies Creative Biolabs is a specialized manufacturer of bispecific antibodies based on our advanced technology and years of.

Jacques F.A.P. Miller, Michel Sadelain Cancer Cell

سرطان الثدي Breast Cancer

Specific Defenses of the Host: The Immune Response

Sections to Skip for Ch 2 Figure Enzyme digestion of Ab’s

Display-O-Matic Think Outside the Cell.

Advances in Specific Immunotherapy for Prostate Cancer

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Figure 1 Chimeric antigen receptor (CAR) structures

Differentiation and Functions of CD8+ Effector T Cells

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Molecular approaches to HER2 targeted therapy

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases.

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Figure e-1 A B C Wild-type TDP-43 G3BP Merge+DAPI

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

The absence of ADCC by nivolumab in vitro.

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against Autologous Malignant Cells in Sezary Syndrome Patients Jean-David Bouaziz,

Kabir A. Khan, Robert S. Kerbel Cancer Cell

Taia T. Wang, Jeffrey V. Ravetch Immunity

The PbGAPDH G6 fragment interacts with recombinant CD68.

Expression of SYCE2 inhibits the interaction of HP1α with H3K9me3.

ADCC by T lymphocytes after transfection.

Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell. Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell.

Model of EphA/ephrin-A expression in GBM.

What’s your nationality? Where are you from?

Vaccines for Lung Cancer

Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.

Anti-CD20-IL-21 fusokine: the tail wags the dog

Schematic illustration showing the proposed mechanism of trastuzumab.

Specific inhibition of the Fab-HLA-A2/Flu induction of CTL mediated tumor cell lysis by a competing antibody. Specific inhibition of the Fab-HLA-A2/Flu.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Target-dependent T cell–mediated cytotoxicity of HER2-TDB.

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

Presentation transcript:

ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody with a His-tag at the C- terminus. Exists as a monomer under non- reducing and reducing condition. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as Gastric and esophageal cancers, breast cancer.